Cargando…
Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function
The small GTPase KRAS, which is frequently mutated in human cancers, must be localized to the plasma membrane (PM) for biological activity. We recently showed that the KRAS C-terminal membrane anchor exhibits exquisite lipid-binding specificity for select species of phosphatidylserine (PtdSer). We,...
Autores principales: | Kattan, Walaa E, Chen, Wei, Ma, Xiaoping, Lan, Tien Hung, van der Hoeven, Dharini, van der Hoeven, Ransome, Hancock, John F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Life Science Alliance LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709719/ https://www.ncbi.nlm.nih.gov/pubmed/31451509 http://dx.doi.org/10.26508/lsa.201900431 |
Ejemplares similares
-
Glycolysis regulates KRAS plasma membrane localization and function through defined glycosphingolipids
por: Liu, Junchen, et al.
Publicado: (2023) -
Discovery of High-Affinity Noncovalent Allosteric
KRAS Inhibitors That Disrupt Effector Binding
por: McCarthy, Michael J., et al.
Publicado: (2019) -
Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity
por: Adhikari, Hema, et al.
Publicado: (2021) -
KRAS Inhibitor
that Simultaneously Inhibits Nucleotide
Exchange Activity and Effector Engagement
por: Pagba, Cynthia V., et al.
Publicado: (2022) -
Speculations on the activation of ROS generation in C. elegans innate immune signaling
por: van der Hoeven, Ransome, et al.
Publicado: (2012)